Search

As summer morphs into fall and Wall Street returns to full operation, I’m seeing some welcome signs of buying in the cannabis sector. So today we’ll join them, by averaging up in two of our holdings.

Last year, I started writing a series explaining our investment advisories in an effort to help answer one of the most common questions we get from investors, “Which Cabot publication is right for me?” Also last year, we expanded the Cabot family by purchasing Dick Davis Digest and Income Digest. This is what Timothy Lutts wrote at the time: “Now, it’s our honor to be the steward of these well-respected publications. Our goal is to honor the past reputation of these Digests, while improving the newsletters so they serve subscribers better in this Internet age. I’ll be telling you much more about these Digests in the future.”

I wrote to you a few months ago about our venture into video. Today, I’m presenting you with Cabot’s very first weekly stock market review with Michael Cintolo.

Forget the Dora the Explorer, Hannah Montana and the Jonas Brothers, kids will soon have a new idol to emulate in the form of a new cartoon series starring ... Warren Buffett. No, your eyes aren’t playing tricks on you. The famed billionaire investor is the star of a new online cartoon series aimed at teaching children about financial responsibility. (After the credit crisis, housing market debacle and stock market meltdown last year, it seems like more than just kids would benefit from this series.)

Thank you for subscribing to the Cabot Undervalued Stocks Advisor. We hope you enjoy reading the October 2022 issue.

Following the sharp drop in stocks due to fears of a major policy error, we see an opportunity for subscribers to add to their existing positions in many of our recommended names at very attractive prices.

Is a deep recession likely? Perhaps we are instead experiencing an old-fashioned inventory cycle.

Please feel free to send me your questions and comments. This newsletter is written for you and the best way to get more out of the letter is to let me know what you are looking for.

I’m best reachable at Bruce@CabotWealth.com. I’ll do my best to respond as quickly as possible.

The evidence for the overall market continues to improve; over the past week, two blastoff indicators have turned green, which should bode well when looking out over the next few months. Growth stocks, however, remain in a consolidation phase following some huge runs, with many (not all) stocks sagging back during the past week or two. Overall, though, the pullbacks have been normal, so we remain optimistic, though we’re still stepping slowly and looking for decent entry points.

In tonight’s issue, we’re doing a touch more buying, filling out a position in one of our stocks, following the addition of a full position last week. That will leave us with around 18% in cash.

It was 2007 when James Morales first realized he had sleep apnea. For over a decade he frequently stopped breathing at night, struggled in life and at work due to chronic fatigue, and his wife was always worried about what could happen if he didn’t get help.
Today, James sleeps like a baby. He rocks out of bed, attacks the day doing house projects and in his job. The best thing is he’s not relying on a CPAP machine – complete with hoses and a face mask – to deal with the sleep apnea.

What was his solution?
It’s all laid out in the October Issue of Cabot Small-Cap Confidential.

Current Market Outlook


The market had put together a few small positive steps heading into last week, but after a solid G20-induced rally on Monday, it’s been all selling, all the time—the intermediate-term trend has rejoined the longer-term trend in bearish territory, with some indexes (including the S&P 500 today) hitting new correction lows. Because of that, we’re moving our Market Monitor back down a notch to a level 4 and advise remaining in a defensive stance. That said, it’s not all bad news; we’re seeing more stocks that are resisting the market’s pull (forming significantly higher lows), and many indexes are still being defended at their October/November lows. Bottom line, it’s best to take things day-by-day and go with the evidence—which, today, means holding plenty of cash.

This week’s list, though, is a good place to start building a watch list if you’ve yet to do so, as many of these stocks look like they want to move higher if the market gets going. Our Top Pick is MongoDB (MDB), a stock that actually nosed to new highs after earnings before pulling back in.

Stock Name	Price	Buy Range	Loss Limit
Guardant Health (GH)	88.34	42-44.5	36.5-38
Kirkland Lake Gold (KL)	51.30	22-23.5	20-21
LHC Group (LHCG)	103.10	97.5-100	89-91
MongoDB (MDB)	156.56	80-84	70-72.5
Okta, Inc. (OKTA)	148.41	61-64.5	54-56
RH Inc. (RH)	252.93	132-138	119-123
Shopify (SHOP)	585.00	143-150	130-134
Spirit Airlines (SAVE)	57.03	57.5-60.5	52-53.5
Vanda Pharmaceuticals (VNDA)	31.04	26-28	22.5-23.5
Zscaler (ZS)	126.22	38.5-41	33.5-35.5

September selling is already underway. Just remember that it’s almost always temporary. The S&P 500 has been down at least 4% after Labor Day in each of the last four years, with a bottom coming sometime in October. All four times, it has eclipsed pre-Labor Day levels by the third week of November. Thankfully, our portfolio enters September in very good shape, with 12 stocks up double-digit percentages and four others up by at least triple digits. To help weather another potential September storm, today we add a “safer” dividend stock recently recommended by Chief Analyst Tom Hutchinson to his Cabot Dividend Investor audience.

Details inside.

While the market mourns the misfortunes of poor Mark Zuckerberg, we actually have a little ray of light in emerging markets, as the Cabot Emerging Markets Timer is showing a very new green light. New buy signals are pretty delicate, but we’re taking this one seriously, doing a little new buying and shifting another stock from a Hold to a Buy rating. As the artillery of the trade war rumbles, it’s nice to have something to celebrate. Read on for details.

Things are looking up for emerging market equities. They’re not fully healthy, yet, but there has been definite improvement since the August 16 low. In today’s issue, I have some thoughts about whether or not this is a bottom in emerging markets, and how we will know one when it appears. I also have an intriguing new IPO for you to consider.

While we have yet to get a buy signal from the Cabot Emerging Markets Timer, our stocks are generally performing very well and we have only a couple of quarterly reports yet to come. In today’s issue, I talk about the trouble with too much news and write up a Chinese financial company that has a powerful head of steam up, with only a Q1 report to worry about.

The bull market remains alive and well, with most stocks and sectors in good shape, so we\'re generally letting our winners run and staying heavily invested. That said, January is often a tricky month, so with the potential for potholes and volatility, tonight\'s Cabot Stock of the Week is a mega-cap growth stock that, by some measures, is undervalued.

The Cabot Emerging Markets Timer is sitting firmly on the fence and some of our stocks are taking breathers. It’s not anything like a time to over-react, but we’re pulling in our horns in an appropriate way. We also have a new stock that does a brilliant job of balancing a national presence with thorough local focus.

In today’s issue, I dig into the reasons behind this painful correction, finding an aggravating Chinese government regulatory shift that can account for a large part. Despite the turmoil, the Cabot Emerging Market Timer is still positive, and I have a fresh, young Chinese tech stock that has enormous potential as the development of the Chinese cloud continues.